Role of Anticoagulant Therapy in Pregnant Women with Antiphospholipid Antibody Syndrome

Le résumé fourni par la source

Background: When there is at least one kind of circulating antiphospholipid antibody (aPL), the patient may experience pregnancy morbidity, arterial or venous thrombotic events, and an autoimmune condition known as antiphospholipid syndrome (APS). Aim and objectives: To detect the role of the administration of anticoagulant drugs in women with APS in improving pregnancy outcomes and its effect on the rate of live births. Patient and methods: Our study was a prospective randomized control trial. carried out on 80 pregnant ladies and attended El Hussin Hospital Department of Gynecology & obstetrics of Al Azhar University Hospitals with lupus anticoagulant and anticardiolipin immunoglobulin antibody testing consistently positive from January 2022 - January 2022. Results: There was a significant difference between the two studied groups as regards miscarriages, EGA at loss, live birth, birth weight, Pre-eclampsia, prematurity, fetal death, and hyperbilirubinemia. Concerning preterm delivery, maternal age, small for gestational age, placental abruption, and (NICU) admission, no statistically significant difference was found between the two groups. There was a statistically significant difference between the two groups regarding birth weight and EGA. Conclusion: Compared with aspirin, heparin significantly improved live birth, age at delivery during gestation, reduced IUGR occurrence, miscarriage, and pre-eclampsia. There are no significant risks to either the mother or the unborn child when using LMWH during pregnancy to avoid RM in women with APS compared to low-dose aspirin (LDA).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.